Nektar Therapeutics
NASDAQ:NKTR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nektar Therapeutics
Nektar Therapeutics
Additional Paid In Capital
Nektar Therapeutics
Additional Paid In Capital Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Additional Paid In Capital
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Additional Paid In Capital
$45.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
85%
|
CAGR 10-Years
41%
|
|
|
Pfizer Inc
NYSE:PFE
|
Additional Paid In Capital
$93B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Additional Paid In Capital
$44.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Additional Paid In Capital
$7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
See Also
What is Nektar Therapeutics's Additional Paid In Capital?
Additional Paid In Capital
3.6B
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Additional Paid In Capital amounts to 3.6B USD.
What is Nektar Therapeutics's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
7%
Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Nektar Therapeutics have been 2% over the past three years , 3% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
